Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

BACKGROUND: Central nervous system (CNS) metastases is inevitable for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). AZD3759 is a novel EGFR-TKI with impressive CNS penetration. METHODS: We initiated a phase 2, multi-center, umbrella trial (CTONG1702, NCT03574402)...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggie Liu, Si-Yang, Dong, Xiao-Rong, Wang, Zhen, Du, Yingying, Cui, Jiu-Wei, Chu, Qian, Xu, Bing-Fei, Zheng, Ming-Ying, Deng, Jia-Yi, Lu, Chang, Wei, Xue-Wu, Li, Yang-Si, Zheng, Mei-Mei, Yang, Ming-Yi, Huang, Jie, Li, Anna, Bai, Xiao-Yan, Sun, Yue-Li, Xu, Chong-Rui, Wang, Bin-Chao, Chen, Hua-Jun, Yang, Jin-Ji, Yan, Hong-Hong, Zhong, Wen-Zhao, Zhou, Qing, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541475/
https://www.ncbi.nlm.nih.gov/pubmed/37781161
http://dx.doi.org/10.1016/j.eclinm.2023.102238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541475/
https://www.ncbi.nlm.nih.gov/pubmed/37781161
http://dx.doi.org/10.1016/j.eclinm.2023.102238

Ejemplares similares